Related Experiment Videos
L-5-hydroxytryptophan for LSD-induced psychosis
The American Journal of Psychiatry
|April 1, 1983
Summary
L-5-hydroxytryptophan, a serotonin precursor, successfully treated LSD-induced psychosis in a patient. This suggests serotonin deficiency may play a role in some LSD-related psychotic disorders.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Lysergic acid diethylamide (LSD) can induce psychotic symptoms.
- The exact neurochemical mechanisms underlying LSD-induced psychosis are not fully understood.
- Serotonin is a key neurotransmitter implicated in mood and perception.
Observation:
- A case study involved a 23-year-old male experiencing LSD-induced psychosis.
- The study employed a randomized, double-blind crossover design comparing L-5-hydroxytryptophan to a placebo.
- L-5-hydroxytryptophan is a direct precursor to serotonin.
Findings:
- L-5-hydroxytryptophan administration led to the reversal of psychotic symptoms.
- The patient's symptoms significantly improved following treatment with the serotonin precursor.
- A placebo did not produce a similar therapeutic effect.
Implications:
- This finding supports the hypothesis that a relative central nervous system (CNS) serotonin deficiency may contribute to LSD-induced psychosis.
- L-5-hydroxytryptophan may represent a potential therapeutic agent for managing specific types of drug-induced psychosis.
- Further research is warranted to explore the role of serotonin in psychedelic-induced mental health conditions.